NYSE - Nasdaq Real Time Price USD

Rafael Holdings, Inc. (RFL)

1.0800 +0.0400 (+3.85%)

At close: November 9 at 4:00:03 PM EST

 All 
 News 
 Earnings Calls 
 Press Releases 
 SEC Filings 

Rafael Holdings to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

GlobeNewswire 6d ago

RFL
+2.88%
RFL-WT
Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update

GlobeNewswire 11d ago

RFL
+2.88%
RFL-WT
Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type C

GlobeNewswire 11d ago

RFL
+2.88%
RFL-WT
Rafael’s Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing

MarketBeat 1mo ago

RFL
+2.88%
Rafael Holdings Shares Fall 25% After Trappsol Cyclo Phase 3 Trial Misses Primary Endpoint

InvestorsHub 1mo ago

RFL
+2.88%
Rafael Holdings stock tumbles 25% as drug trial misses goal

Investing.com 1mo ago

RFL
+2.88%
Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)

GlobeNewswire 1mo ago

RFL
+2.88%
RFL-WT
Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

GlobeNewswire 4mo ago

RFL
+2.88%
RFL-WT
Rafael Holdings Insider Ups Holding By 1,810% During Year

Simply Wall St. 6mo ago

RFL
+2.88%
Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”

GlobeNewswire 6mo ago

RFL
+2.88%
Cyclo goes forth with Niemann-Pick drug’s approval bid despite Phase III miss

Clinical Trials Arena 1mo ago

RFL
+2.88%
Israel said to eye US listing for major defense firms

Investing.com 4mo ago

RFL
+2.88%

Performance Overview

Return	RFL	S&P 500 (^GSPC)
YTD	-8.47%	+10.29%
1-Year	-16.28%	+12.20%
3-Year	-37.78%	+73.67%

U.S. markets closed

Rafael Holdings, Inc. (RFL)

Rafael Holdings to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2026 Financial Results and Provides Corporate Update

Rafael Holdings Announces Submission of New Drug Application to FDA for Trappsol® Cyclo™ (remibetadex) for the Treatment of Niemann-Pick Disease Type C

Rafael’s Trappsol Cyclo Misses Primary Endpoint, Targets 2026 FDA Filing

Rafael Holdings Shares Fall 25% After Trappsol Cyclo Phase 3 Trial Misses Primary Endpoint

Rafael Holdings stock tumbles 25% as drug trial misses goal

Rafael Holdings Announces Topline Results from the Pivotal Phase 3 TransportNPC™ Study of Trappsol® Cyclo™ in Niemann-Pick Disease Type C (NPC)

Rafael Holdings Reports Third Quarter Fiscal 2026 Financial Results

Rafael Holdings Insider Ups Holding By 1,810% During Year

Rafael Holdings Announces Patent Licensing Agreement with MIT for “Small Molecules to Improve Myelination in ApoE4 positive Alzheimer’s Disease”

Cyclo goes forth with Niemann-Pick drug’s approval bid despite Phase III miss

Israel said to eye US listing for major defense firms